Clinical Trials in Vladivostok, Russia

9 recruiting

Showing 19 of 9 trials

Recruiting

Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

Breast Cancer
Novartis Pharmaceuticals2,766 enrolled34 locationsNCT06930859
Recruiting

Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study

Uncontrolled Asthma
AstraZeneca9,000 enrolled47 locationsNCT06521229
Recruiting

Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

Severe Asthma
AstraZeneca5,000 enrolled40 locationsNCT06472310
Recruiting

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia

Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
AstraZeneca2,000 enrolled41 locationsNCT05887011
Recruiting
Phase 2

Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease

Crohn's Disease (CD)
Biocad204 enrolled20 locationsNCT07078994
Recruiting
Phase 2

Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis (UC)
Biocad198 enrolled20 locationsNCT07080034
Recruiting

The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.

Coronary Heart DiseaseChronic Obstructive Pulmonary DiseaseChronic Kidney Diseases+10 more
Russian Federation of Anesthesiologists and Reanimatologists16,000 enrolled38 locationsNCT03945968
Recruiting
Phase 1Phase 2

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Multiple MyelomaPlasmacytoma
Shenzhen Geno-Immune Medical Institute20 enrolled2 locationsNCT06429150
Recruiting
Phase 1

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute10 enrolled2 locationsNCT06435910